Blinatumomab for Pediatric High-Risk B-Cell Precursor Acute Lymphoblastic Leukemia: Safety, MRD Response and Survival in a Single-Center Retrospective Cohort [Removal].
This record is a removal/retraction notice for an article concerning blinatumomab in pediatric high-risk B-cell precursor acute lymphoblastic leukemia and reports no evaluable study findings.
Open original publication →What the AI sees
This record is a removal/retraction notice for an article concerning blinatumomab in pediatric high-risk B-cell precursor acute lymphoblastic leukemia and reports no evaluable study findings.
Research significance
No therapeutic hypothesis can be supported from this record; although the removed article's title referenced blinatumomab, MRD response, safety, and survival, the supplied notice provides no underlying evidence and those title-level claims should not be interpreted as valid findings.
Source abstract
[This retracts the article DOI: 10.2147/ITT.S603087.].